Improving Ventilatory Capacity in Those With Chronic High Level SCI (NCT05041322) | Clinical Trial Compass
CompletedPhase 2
Improving Ventilatory Capacity in Those With Chronic High Level SCI
United States13 participantsStarted 2020-11-29
Plain-language summary
The purpose of this study is to find out if taking the drug Buspar will increase breathing capacity in individuals with spinal cord injuries.
Who can participate
Age range18 Years – 50 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Chronic high-level SCI (at least 24-months post injury)
* Age 18 to 50 years.
* Medically stable
* Spinal Cord Injury ≥T3
* American Spinal Injury Association grade A or B or C.
* Able to perform arm crank exercise.
Exclusion Criteria:
* Cardiomyopathy
* High blood pressure( \>140/90 mmHg or you are taking high blood pressure medication)
* Significant irregular heartbeat
* Heart disease
* Chronic lung disease (COPD, bronchitis)
* Current use of cardioactive or antidepressant drugs
* Family history of significant irregular heart beat or sudden cardiac death
* Orthostatic hypotension (symptomatic fall in blood pressure \>30 mmHg when upright)
* Current grade 2 or greater pressure ulcers at relevant contact site
* Neurological disease (stroke, peripheral neuropathy, myopathy)
* Arm or shoulder conditions that limit ability to perform arm crank exercise
* History of bleeding disorder, diabetes, kidney disease, cancer, other neurological disease
* Recent weigh change (greater than 10 pounds)
* Regular use of tobacco
* Intrathecal baclofen pump,
* Current use of cardioactive, antidepressant, other sedating agents
* Suicidal ideation
* Pregnant and/or breastfeeding women.
In addition, subjects must have no known hypersensitivity to Buspar and must not be taking a monoamine oxidase inhibitor.